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Translational readthrough, observed primarily in less
complex organisms from viruses to Drosophila, ex-
pands the proteome by translating select transcripts
beyond the canonical stop codon. Here, we show
that vascular endothelial growth factor A (VEGFA)
mRNA in mammalian endothelial cells undergoes
programmed translational readthrough (PTR) gener-
ating VEGF-Ax, an isoform containing a unique
22-amino-acid C terminus extension. A cis-acting
element in the VEGFA 30 UTR serves a dual function,
not only encoding the appended peptide but also
directing the PTR by decoding the UGA stop codon
as serine. Heterogeneous nuclear ribonucleoprotein
(hnRNP) A2/B1 binds this element and promotes
readthrough. Remarkably, VEGF-Ax exhibits antian-
giogenic activity in contrast to the proangiogenic ac-
tivity of VEGF-A. Pathophysiological significance of
VEGF-Ax is indicated by robust expression in multi-
ple human tissues but depletion in colon adenocarci-
noma. Furthermore, genome-wide analysis revealed
AGO1 andMTCH2 as authentic readthrough targets.
Overall, our studies reveal a novel protein-regulated
PTR event in a vertebrate system.INTRODUCTION
Vascular endothelial growth factor A (VEGF-A) inducesmigration
and proliferation in vascular endothelial cells (ECs) and is essen-
tial for both physiological (e.g., embryogenesis) and pathological
(e.g., tumorigenesis, retinopathy, and arthritis) angiogenesis
(Ferrara, 2009; Hicklin and Ellis, 2005; Nagy et al., 2007). ECs
not only respond to VEGF-A but also express and secrete it,
and EC-derived VEGF-A exhibits an intracellular activity essen-
tial for vascular homeostasis (Lee et al., 2007). VEGF-A also
increases vascular permeability (Senger et al., 1983) and isrequired for maintenance of the differentiated phenotype in
ECs (Kamba et al., 2006). Deletion of the VEGFA gene, even at
a single allele, or a 2-fold increase of VEGF-A is embryonic
lethal, demonstrating a precise VEGF-A dosage requirement
during development (Carmeliet et al., 1996; Ferrara et al.,
1996; Miquerol et al., 2000). VEGF-A functions primarily through
two tyrosine kinase receptors, VEGFR1 (or flt-1) and VEGFR2 (or
KDR or flk-1), and neuropilin 1 serves as an important coreceptor
(Soker et al., 1998). Because VEGF-A is critical for the pathogen-
esis of vascularized solid tumors, agents that selectively target
the protein, receptor, or signaling pathway have received sub-
stantial attention. As an example, bevacizumab, a monoclonal
antibody that targets human VEGF-A, is an FDA-approved
drug successfully used to treat metastatic colorectal cancer
(Hurwitz et al., 2004).
The VEGFA gene on human chromosome 6 comprises eight
exons. Alternative splicing events at the sixth and seventh exons,
which encode heparin-binding motifs, generate multiple iso-
forms, all of which exhibit proangiogenic activity. Interestingly,
an alternative splicing event within exon 8 has been reported
to generate an antiangiogenic isoform, termed VEGF-Ab (Bates
et al., 2002; Harper and Bates, 2008). The splicing event in
VEGFAb mRNA replaces an exon encoding CDKPRR at the C
terminus of canonical proangiogenic isoforms with SLTRKD
(RLTRKD in B. taurus). VEGF-A expression is regulated by mul-
tiple posttranscriptional mechanisms, primarily involving the
unusually long 30 UTR. Heterogeneous nuclear ribonucleoprotein
(hnRNP) L binds a CA-rich element, promoting VEGFA mRNA
stability under hypoxia (Shih and Claffey, 1999). VEGF-A expres-
sion is also subject to exquisite translational control mecha-
nisms. In one well-studied example, interferon-g stimulation
of myeloid cells induces binding of the heterotetrameric GAIT
(interferon-g-activated inhibitor of translation) complex to a
cognate element in the VEGFA 30 UTR and inhibits its translation
(Mazumder et al., 2003; Sampath et al., 2004). A protein-directed
RNA switch integrates disparate signals induced by hypoxia and
interferon-g to further regulate VEGFA translation expression in
myeloid cells (Ray et al., 2009). Interestingly, a mechanism that
prevents complete translational silencing of VEGFA mRNA has
been reported that forces a ‘‘trickle’’ of synthesis, underscoringCell 157, 1605–1618, June 19, 2014 ª2014 Elsevier Inc. 1605
the requirement for precise regulation of VEGF-A dosage in
physiological conditions (Yao et al., 2012). In addition, VEGFA
mRNA is subject to 50 UTR-mediated regulation in which an inter-
nal ribosomal entry site drives alternative translation-initiation
from an in-frame CUG codon (Huez et al., 2001).
Translation of mRNAs normally terminates at an in-frame
stop codon. However, in a few circumstances, translation can
continue beyond the stop codon to a downstream stop codon,
generating a C-terminal polypeptide extension. Such transla-
tional readthrough events are best understood in viruses (Li
and Rice, 1989; Pelham, 1978), but translational readthrough
has also been observed in bacteria (Jalajakumari et al., 1989),
yeast (Namy et al., 2003), andDrosophila (Dunn et al., 2013; Rob-
inson and Cooley, 1997; Steneberg and Samakovlis, 2001). In
a few systems translational readthrough is ‘‘programmed’’ by
cis-acting RNA elements downstream of the first stop codon,
clearly distinguishing the process from readthrough resulting
from errors of translation (Firth et al., 2011). Limited evidence
for readthrough of vertebrate mRNAs has been shown, namely,
rabbit b-globin in rabbits and rat myelin protein zero; however,
the functional significance of the readthrough products and the
cis-acting RNA signals or other regulatory mechanisms have
not been determined (Chittum et al., 1998; Yamaguchi et al.,
2012). Moreover, to our knowledge, trans-acting protein factors
that bind RNA elements or otherwise regulate translational read-
through have not been observed.
Here, we demonstrate that VEGFA mRNA undergoes robust
programmed translational readthrough (PTR) in mammalian
ECs. The PTR event generates a VEGF-A isoform, termed
VEGF-Ax (for ‘‘extended’’), with a 22-amino-acid C terminus
extension. Remarkably, VEGF-Ax exhibits a function opposite
to that of VEGF-A, namely, antiangiogenic activity. Readthrough
is ‘‘programmed’’ by a 63 nt RNA segment following the canon-
ical stop codon that serves a dual function, encoding the peptide
extension of VEGF-A and also acting as a cis-acting regulatory
element. hnRNP A2/B1 binds this element and promotes read-
through. The presence of VEGF-Ax in blood and its selective
expression in multiple tissues, as well as differential expression
in a solid tumor, indicate its pathophysiological significance.
Recombinant VEGF-Ax reduced tumor progression and associ-
ated angiogenesis in a human xenograft tumor implanted in
nude mice, demonstrating its antiangiogenic property in vivo.
We have expanded the generality of our findings by a genome-
wide analysis that reveals additional validated readthrough tar-
gets, namely, AGO1 and MTCH2 mRNAs. Overall, our results
not only demonstrate a novel PTR event in a vertebrate transcript
but also identify a new antiangiogenic isoform of VEGF-A with a
potential role as a suppressor of pathological angiogenesis.
RESULTS
Endothelial Cells Express and Secrete an
Antiangiogenic Isoform of VEGF-A
Despite recent studies of the autocrine function of EC-derived
VEGF-A in blood vessel angiogenesis and homeostasis (da Silva
et al., 2010; Lee et al., 2007), its paracrine function has not
received much attention. We hypothesized that secreted,
EC-derived VEGF-A might be an important contributor to EC1606 Cell 157, 1605–1618, June 19, 2014 ª2014 Elsevier Inc.migration and proliferation, which are essential for endothelial
wound-healing responses and angiogenesis (Ausprunk and
Folkman, 1977; Schwartz et al., 1978). Unexpectedly, a VEGF-
A-neutralizing antibody enhanced migration of bovine aortic
ECs as indicated by the number of migrating cells in a razor-
wound assay, as well as by root-mean-square displacement
and mean cell speed (Figure 1A). Likewise, the antibody
increased EC proliferation determined fluorimetrically as total
cell DNA (Figure 1B). Consistent with these observations, addi-
tion of EC-conditioned medium decreased EC migration (Fig-
ure 1C). These surprising results indicate that EC-derived
VEGF-A inhibits their own migration and proliferation, character-
istic features of antiangiogenic VEGF-A isoforms. To test for the
possible expression of VEGF-Ab isoforms, we sequenced 74
VEGFA cDNA clones frombovine aortic ECs (and six frommouse
aortic ECs) but did not find VEGF-Ab-specificmRNA or any alter-
natively spliced VEGFAmRNA that can generate antiangiogenic
isoforms. Instead, we identified only mRNAs corresponding to
proangiogenic VEGF-A164 and VEGF-A120 (Figures S1A–S1C
available online). Similarly, VEGF-Ab-specific mRNA was not
detected by RT-PCR using primers designed to differentiate
between VEGF-Ab and VEGF-A isoforms (Figure S1D).
VEGF-Ax Is a Novel Isoform Generated by Translational
Readthrough of VEGFA mRNA
The paradoxical presence of antiangiogenic VEGF-A in the
absence of VEGF-Ab-specific mRNA suggested the possibility
of a novel antiangiogenic VEGF-A isoform generated from
mRNA encoding the proangiogenic isoform. A critical clue was
offered by the sequence of the VEGFAmRNA 30 UTR. In the hu-
man VEGFA 30 UTR, we observed an evolutionarily conserved
UGA stop codon 63 nt downstream and in frame to the canonical
stop codon (Figure 1D). Importantly, a 4 nt insertion in rodent 30
UTRs is offset by a 1 nt deletion, thereby preserving the in-frame
nature of the stop codons. Moreover, a mutation in the down-
stream rodent stop codon generates the alternate UAA stop
codon, providing additional evolutionary support for the signifi-
cance of the in-frame stop codon. The amino acid sequence
potentially encoded by the region between the stop codons is
likewise conserved in mammals, but the sequence beyond the
downstream stop codon exhibits weak conservation (Figures
S1E and S1F). Based on these observations, we hypothesized
that VEGFAmRNA translationmight extend beyond its canonical
stop codon, terminating at the downstream, in-frame stop
codon. This translational readthrough event in human or bovine
cells would generate a VEGF-A isoform containing a 22-amino-
acid C terminus extension (including an amino acid replacement
of the stop codon) ending with S/RLTRKD, the same six-amino-
acid terminus reported to confer antiangiogenic activity in human
VEGF-Ab (Figure 1E).
To test this hypothesis, we generated an antibody against
the unique peptide, AGLEEGASLRVSGTR, generated by the pro-
posed translational readthrough event and not present in VEGF-
Ab or any other protein (or in silico-translated mRNA). A 20 kDa
protein corresponding to the predicted size of the readthrough
product, designated VEGF-Ax (for extended), was identified in ly-
sates from bovine ECs (Figure 2A). Expression was inhibited by




Figure 1. ECs Express and Secrete an Anti-
angiogenic Isoform of VEGF-A
(A) Neutralizing anti-VEGF-A antibody enhances
EC migration. Shown are ECs migrating across
razor-wound line (mean ±SE, n = 3) (left), individual
cell trajectories and root-mean-square displace-
ment (center), and cell speed in the presence of
anti-VEGF-A antibody (n = 71) and immunoglobulin
G (n = 52) (right).
(B) Neutralizing anti-VEGF-A antibody increases
EC proliferation. Cell amount was determined flu-
orimetrically as DNA (mean ± SE, n = 4).
(C) EC-derived conditioned medium inhibits EC
migration. EC migration determined by razor-
wound assay (mean ± SE, n = 3).
(D) Conservation of VEGFA 30 UTR proximal region
(gray); canonical and downstream, in-frame stop
codons in mammals (boxed).
(E) Schematic showing generation of VEGF-A,
VEGF-Ab, and VEGF-Ax isoforms.
See also Figure S1.RNAs (siRNAs), consistentwith a VEGF-A isoform. Protein immu-
noprecipitated with anti-VEGF-Ax antibody was recognized by
an anti-VEGF-A antibody that targets the N terminus, further
verifying VEGF-Ax as a VEGF-A isoform (Figure 2B). To validate
antibody specificity, human embryonic kidney 293 (HEK293)
cells were transfected with myc-tagged VEGFA cDNA up to the
downstream stop codon in which the canonical stop codon
was replaced by Ala-encoding GCA to ensure efficient genera-
tion of the modified, extended isoform, denoted VEGF-AxAla.
Anti-VEGF-Ax antibody recognized VEGF-AxAla, but not VEGF-
A, whereas anti-VEGF-A antibody recognized both isoforms
(Figure S2A). As expected, anti-VEGF-Ax antibody did notCell 157, 1605–161recognize recombinant VEGF-Ab; how-
ever, anti-VEGF-Ab antibody did recog-
nize VEGF-AxAla (Figure S2B). Finally,
preadsorption of anti-VEGF-Ax antibody
with AGLEEGASLRVSGTR peptide pre-
vented recognition of the 20 kDa VEGF-
Ax band, further validating antibody
specificity (Figure S2C). VEGF-Ax expres-
sion also was observed in murine aortic
and human umbilical vein ECs (Figure 2C)
and in multiple other cell types including
macrophages, hepatocytes, keratino-
cytes, and tumor-derived cell lines (Fig-
ure S2D). To distinguish between VEGF-
Ax and VEGF-A by protein molecular
weight, EC lysates were deglycosylated,
subjected to 16% Tricine gel electro-
phoresis, and immunoblotted with anti-
VEGF-A and anti-VEGF-Ax antibodies.
VEGF-Ax constitutes about 10% of all
VEGF-A isoforms in EC lysates; however,
VEGF-Ax is the predominant isoform in
conditioned medium, constituting about
85% of the total (Figure 2D).Translational readthrough in VEGFAmRNA was further estab-
lished by mass spectrometric analysis of the product generated
by overexpressing in HEK293 cells VEGFA cDNA containing the
canonical stop codon and the Ax-specific sequence upstream
of a myc-His tag to facilitate purification. In addition to detection
of VEGF-A-specific peptides, selected reaction monitoring re-
vealed a spectrum consistent with RSAGLEEGASLR (S, Ser in
place of stop codon) specific for the readthrough region; the pro-
file was confirmed by the spectrum obtained from synthetic
RSAGLEEGASLR peptide (Figures 2E–2G). Spectra consistent
with Ser in place of the stop codon were observed in three out





Figure 2. VEGF-Ax Is a Novel Isoform of
VEGFA Generated by Translational Read-
through
(A) VEGFA-specific siRNAs inhibit VEGF-Ax
expression. Bovine ECs were transfected with
three different VEGFA-specific siRNAs and VEGF-
Ax in cell lysates determined by immunoblot with
anti-VEGF-Ax antibody.
(B) VEGF-Ax is an authentic VEGF-A isoform.
Lysates from bovine EC were immunoprecipi-
tated with anti-VEGF-Ax antibody or preimmune
(Pre-imm.) serum and subjected to immunoblot
analysis with anti-VEGF-Ax and anti-VEGF-A
antibodies.
(C) VEGF-Ax is expressed by murine aortic ECs
(MAEC), bovine aortic ECs (BAEC), and human
umbilical vein ECs (HUVEC). Cell lysates were
subjected to immunoblot analysis with anti-VEGF-
Ax antibody.
(D) Separation of VEGF-Ax and VEGF-A isoforms
in ECs. BAEC lysates (left) and conditioned media
(right) were deglycosylated and resolved on 16%
Tricine gel before immunoblot analysis with anti-
VEGF-Ax and anti-VEGF-A antibodies.
(E) Amino acid sequence of VEGF-Ax. Peptides
identified by mass spectrometry (underline),
readthrough region (bold), and recoded Ser
(boxed) are highlighted.
(F) Identification of VEGFA mRNA readthrough
product by tandem mass spectrometry (MS/MS).
A MS/MS spectrum was identified consistent with
RSAGLEEGASLR (readthrough amino acid is un-
derlined). The spectrum contains a total of nine
C-terminal ‘‘y’’ ions and seven N-terminal ‘‘b’’ ions
consistent with this sequence. The peptide was
a low-abundant component, and the spectrum
contains several contaminant ions (*).
(G) Identity of readthrough peptide validated by
synthetic peptide. RSAGLEEGASLR peptide was
synthesized and theMS/MS spectrumdetermined
as in (F).
See also Figure S2.readthrough peptides containing the other 19 amino acids in
place of the stop codon was negative, supporting Ser insertion
during UGA stop codon readthrough.
Ax Element Is the Necessary and Sufficient cis-Acting
Signal for Translational Readthrough of VEGFA mRNA
To validate translation readthrough and investigate molecular
mechanisms, we established a reporter assay in which the full-
length bovine VEGFA coding sequence (corresponding to
VEGF-A164) up to and including the 63 nt, Ax-specific sequence
(termed Ax element) was cloned upstream of and in frame
with firefly luciferase (FLuc). The downstream stop codon was
excluded so that readthrough at the canonical stop codon
generated a FLuc-containing chimeric protein. Transfected
ECs exhibited substantially greater FLuc activity compared to
vector alone or control reporters lacking the Ax element or re-
placed by a nonspecific sequence, consistent with translation
readthrough (Figure 3A). To calculate readthrough efficiency,
the upstream TGA stop codon was mutated to Ala-encoding1608 Cell 157, 1605–1618, June 19, 2014 ª2014 Elsevier Inc.GCA to maximize FLuc expression; stop codon readthrough
efficiency was about 9%. Quantitative RT-PCR (qRT-PCR) anal-
ysis showed that all constructs were transcribed at similar levels,
indicating that differential FLuc activity was due to differences in
translation. Similar results were obtained by in vitro translation of
the same reporters in rabbit reticulocyte lysates (Figure S3A).
These results verify translational readthrough in VEGFA mRNA
and show the essentiality of the Ax element, consistent with a
PTR mechanism.
To investigate if the Ax element drives readthrough in the
context of a heterologous transcript, a construct was engineered
containing Myc terminated with a TGA stop codon, upstream
and in frame to the Ax element and FLuc (Myc-Ax-FLuc). Trans-
fection into ECs induced substantial FLuc activity compared to a
control transcript without the Ax element or empty vector (Fig-
ure 3B, left). The readthrough product was detected following
immunoprecipitation using anti-Myc-tag antibody by immuno-
blot (Figure 3B, right) and by mass spectrometry (Figure S3B).




Figure 3. Ax Element Is a Necessary and Sufficient cis-Acting Signal for VEGFA mRNA Readthrough
(A) Ax element is sufficient for readthrough of VEGFA chimeric transcript. Plasmid containing in-frame VEGF-Ax-FLuc, and variants with TGA-to-GCA substi-
tution, no Ax element, and Ax replaced by a nonspecific sequence (ns), were transfected into ECs. FLuc activity was normalized to expression of cotransfected
Renilla Luc (top), and FLuc mRNA expression was determined by qRT-PCR (bottom).
(B) Ax element is sufficient for readthrough of heterologous mRNA. Chimeric plasmids containingMyc-Ax-FLuc and variants were transfected into ECs. Relative
FLuc activity and mRNA expression were measured (left). Readthrough product also was determined by immunoprecipitation with rabbit anti-Myc-tag antibody
followed by immunoblot with the mouse anti-Myc-tag antibody (right).
(C) Nucleotide sequence of bovine Ax element. Flanking stop codons (boxes), deletions (horizontal lines), and mutations (arrows) are shown.
(D) Plasmids containing deletions of VEGF-Ax-FLuc were transfected into ECs. FLuc activity was normalized by expression of cotransfected Renilla Luc (top);
FLuc mRNA expression was determined by qRT-PCR (bottom).
(E) All three stop codons permit readthrough. ECswere transfectedwith VEGF-Ax-FLuc constructs containing each stop codon. Relative FLuc activity andmRNA
were determined.
(F) The nucleotide immediately following the canonical stop codon (G1) does not alter readthrough efficiency. ECs were transfected with VEGF-Ax-FLuc con-
structs containing G-to-C, G-to-A, and G-to-T substitutions. Relative FLuc activity and mRNA were measured.
For all graphs, error bars represent SE; n = 3. See also Figure S3.




Figure 4. hnRNP A2/B1 Facilitates VEGFA mRNA Translational Readthrough
(A) Interstop codon sequence (Ax element) of human VEGFA contains a near-consensus hnRNP A2/B1 response element (A2RE).
(B) High-affinity binding of hnRNP A2/B1 to VEGFA A2RE. Surface plasmon resonance analysis of recombinant hnRNP A2/B1 binding to biotinylated RNA
containing VEGFA A2RE immobilized on streptavidin sensor chip (in response units [RU]).
(C) Cytoplasmic localization of hnRNP A2/B1 in ECs. Detection of hnRNP A2/B1 by immunofluorescence (left, with nuclear DAPI stain) and by immunoblot of
fractionated compartments (right). Cyto., cytoplasm; Nucl., nucleus.
(D) hnRNP A2/B1 binds VEGFA mRNA in cells. Immunoprecipitation of hnRNP A2/B1 followed by RT-PCR using VEGFA- and GAPDH-specific primers.
(legend continued on next page)
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shown by in vitro translation in rabbit reticulocyte lysate (Fig-
ure S3C). To determine the region of the Ax element necessary
for function, deletions from both termini were generated (Fig-
ure 3C). Deletion of 9, 21, or 42 nt from the 30 end or 6 nt from
the 50 end substantially reduced FLuc activity, suggesting that
both termini are required, and possibly the entire element, for
efficient readthrough (Figure 3D). Next, we tested the ability of
Ax element to execute readthrough across the other two stop
codons, UAG and UAA. Surprisingly, similar Ax element-medi-
ated VEGFA readthrough was observed across all three stop co-
dons (Figure 3E), thereby rejecting single stop codon-dependent
mechanisms, such as UGA-dependent selenocysteine insertion
(Low and Berry, 1996). Mutation of the first nucleotide after the
canonical stop codon (denoted G1) did not affect the read-
through efficiency, ruling out context-dependent readthrough
mechanisms observed in other systems (Poole et al., 1995;
Tate et al., 1999) (Figure 3F). Together, these experiments reveal
the Ax element as the necessary and sufficient translational
readthrough signal in VEGFA mRNA.
hnRNP A2/B1 Is a trans-Acting Enhancer of VEGFA
Readthrough
A near-consensus hnRNP A2/B1 recognition element (A2RE)
was identified within the Ax element (Figure 4A). hnRNP A2/B1
is an RNA-binding protein involved in pre-mRNA processing
and mRNA transport and binds the consensus sequence 50-
GCCAAGGAGCC-30 (He andSmith, 2009; Shan et al., 2003). Sur-
face plasmon resonance spectroscopy revealed a high-affinity
interaction between hnRNP A2/B1 and a VEGFA RNA segment
containing the A2RE, with a dissociation constant (KD) of 19.2 ±
5.6 nM (Figure 4B). hnRNP A2/B1 is localized primarily in the nu-
cleus; however, cytoplasmic localization was detected by immu-
nofluorescence and by fractionation (Figure 4C). An RNA-binding
protein immunoprecipitation (RIP) experiment confirmed the
intracellular interaction between endogenous hnRNP A2/B1 and
VEGFA mRNA (Figure 4D). To interrogate interaction specificity,
ECs were transfected with a FLuc reporter bearing wild-type,
mutant (AA-to-TT), or no Ax element. RIP followed by qRT-PCR
analysis showed that hnRNP A2/B1 interacted with the wild-
type Ax element, but not with the mutant element (Figure 4E,
left) (Munro et al., 1999). Mutation of the A2RE also substantially
reduced readthrough without altering mRNA expression (Fig-
ure 4E, right). The low-level readthrough in the absence of hnRNP
A2/B1 binding suggests that other factors might contribute,
consistent with the requirement for the entire Ax element, not
just the A2RE. Similarly, siRNA-mediated knockdown of hnRNP
A2/B1 in ECs reduced readthrough of the VEGFA-Ax-FLuc re-
porter without inhibiting FLuc activity of a construct with Ala-en-
coding GCA in place of the canonical stop codon or with mutant(E) hnRNP A2/B1 binds the A2RE in VEGFA mRNA. VEGF-Ax-FLuc plasmid con
Anti-hnRNP A2/B1 immunoprecipitates were probed by qRT-PCR using FLuc- a
FLuc activity and mRNA level are shown (right).
(F) siRNA-mediated knockdown of hnRNP A2/B1 reduces readthrough of Ax elem
and the variant containing A2RE mutation. FLuc activity was measured and FLuc
(G) siRNA-mediated knockdown of hnRNP A2/B1 reduces VEGF-Ax expression. F
were determined by immunoblot analysis and VEGFA mRNA by qRT-PCR.
For all graphs, error bars represent SE; n = 3.Ax element (Figure 4F). Finally, hnRNP A2/B1 knockdown
reduced endogenous expression of VEGF-Ax without affecting
total VEGF-Aprotein ormRNA inECs (Figure 4G). Theseobserva-
tions show the important regulatory role of hnRNP A2/B1 as a
trans-acting factor promoting PTR of VEGFAmRNA.
VEGF-Ax Exhibits Antiangiogenic Properties
Our EC migration and proliferation experiments in the presence
of VEGF-A antibody indicated secretion of an antiangiogenic iso-
form of VEGF-A. Canonical VEGF-A isoforms were not detected
in EC-conditioned medium immunodepleted with anti-VEGF-Ax
antibody, confirming that VEGF-Ax is the predominant isoform
secreted by ECs (Figure S4A). Also, the presence of RLTRKD
(and absence of CDKPRR) at the C terminus suggests that
VEGF-Ax is a novel antiangiogenic isoform. Anti-VEGF-Ax anti-
body increased ECmigration and proliferation to an extent com-
parable to induction by recombinant VEGF-A, consistent with a
paracrine, antiangiogenic activity of endogenous VEGF-Ax (Fig-
ures 5A and 5B; Figure S4B). Purified, recombinant His-VEGF-
AxAla markedly inhibited planar EC migration, tube formation
in Matrigel, and proliferation (Figures 5C–5E). Similarly, siRNA-
mediated knockdown of hnRNP A2/B1, which reduces VEGF-
Ax production, stimulated EC migration (Figure S4C). Together,
these results indicate that VEGF-Ax is the predominant isoform
of VEGF-A released by ECs, exerting a potent paracrine, antian-
giogenic activity. To obtain insights into themechanism of action
of VEGF-Ax, we investigated its binding to VEGF receptors using
solid-phase enzyme-linked receptor-binding assays. His-VEGF-
AxAla and VEGF-A bound VEGFR2, with comparable affinities,
but maximal binding of the former was marginally lower at high
ligand concentration (Figure 5F). Importantly, His-VEGF-AxAla
did not bind neuropilin 1, a critical VEGFR2 coreceptor (Fig-
ure 5G). Likewise, His-VEGF-AxAla did not trigger canonical
signaling pathways as shown by the failure to phosphorylate
VEGFR2 Tyr residues Y1175 and Y951 (Figure 5H).
Pathophysiological Significance of VEGF-Ax
To determine the antiangiogenic function of VEGF-Ax in vivo,
we used human xenograft tumors in nude mice. Administration
of recombinant VEGF-Ax markedly reduced the progression
of HCT116 (human colon carcinoma cell)-derived tumors (Fig-
ure 6A). Furthermore, VEGF-Ax reduced tumor-associated
angiogenesis as measured by the number of vessels directly
feeding the tumors (Figure 6B). To further assess the physiolog-
ical significance of VEGF-Ax, we determined its expression
in vivo using a tissue microarray. VEGF-Ax was detected in
tissue slices from human brain, colon, small intestine, spleen,
and pancreas and from serum from healthy human subjects
(Figures S5A and S5B). Staining of human colon tissue withtaining an Ax element with A2RE mutation (mut. Ax) was transfected into ECs.
nd GAPDH-specific TaqMan probes (left). Readthrough expressed as relative
ent-containing plasmid. ECs were transfected with VEGF-Ax-FLuc construct
mRNA determined by qRT-PCR.
ollowing siRNA-mediated knockdown of hnRNP A2/B1, VEGF-Ax and VEGF-A





(legend on next page)
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Figure 6. Antitumor Properties of VEGF-Ax
(A) Tumor progression in athymic nude mice. Mice
were inoculated with HCT116 cells and treated
subcutaneously with recombinant His-VEGF-Ax
(10 mg/mouse; n = 6 mice, 12 tumors) or buffer (n =
5 mice, 10 tumors) every third day starting from
fourth day after tumor cell inoculation.
(B) Tumor angiogenesis. Representative images
of day 6 HCT116 tumors in athymic nude mice
(top). Number of blood vessels feeding directly into
tumors; whiskers show 5th and 95th percentiles
(bottom; n = 6 mice, 12 tumors in each group).
(C) Immunofluorescence of normal colon and colon
adenocarcinoma. VEGF-Ax and total VEGF-Awere
quantified as integrated, background-subtracted
fluorescence intensity (left); expression in grade 1
(n=6) andgrade2/3 colon adenocarcinoma (n=22)
was normalized to healthy colon (n = 5); whiskers
show 5th and 95th percentiles (right).
See also Figure S5.anti-VEGF-Ax antibody preadsorbed with AGLEEGASLRVSGTR
peptide showed only background signal demonstrating antibody
specificity in tissue immunofluorescence assays (Figure S5C).
VEGF-Ax expression in tissues from pancreatic adenocarci-
noma and glioblastoma was similar to that in corresponding
healthy tissues (data not shown). Remarkably, VEGF-Ax expres-
sion was reduced to near-background level in cancerous tissues
from grade 2 or 3 adenocarcinoma of colon, despite abundant
VEGF-A expression (Figure 6C). These results not only
show that VEGF-A translational readthrough occurs in vivo
but also suggest a possible negative role of VEGF-Ax in tumor
progression.
Genome-wide Analysis of Translational Readthrough
To identify additional translational readthrough candidates
in mammals, we performed a genome-wide bioinformatic anal-
ysis. We interrogated a UTR database (Grillo et al., 2010) for
mammalian transcripts with a stop codon in the 30 UTR in frame
to the canonical stop codon and with amino acid conservationFigure 5. Antiangiogenic Properties of VEGF-Ax
(A and B) Anti-VEGF-Ax antibody increases EC migration and proliferation. (A) EC migration in the presence
VEGF-A (20 ng/ml) was measured by razor-wound assay. (B) Cell proliferation was measured fluorimetricall
(C–E) Antiangiogenic properties of VEGF-Ax. Migration (C), tube formation in Matrigel (D), and proliferation (E)
VEGF-Axala (50 ng/ml).
(F and G) Binding of VEGF-A and His-VEGF-Axala to VEGFR2 (F) and neuropilin 1 (G). Binding was measu
receptor-binding assay.
(H) Phosphorylation status of VEGFR2. HUVECs were treated with VEGF-A and His-VEGF-AxAla for up to 30
For all graphs, error bars represent SE; n = 3. See also Figure S4.
Cell 157, 1605–161in the interstop codon region across
five mammalian species (Figure S6). This
screen revealed VEGFA and five high-
probability readthrough candidates (Fig-
ure 7A). Candidates were tested by trans-
fection of HEK293 cells with a plasmid
containing about 700 nt of the 30 terminus
of the human coding sequence of each
candidate, followed by the interstopcodon sequence and FLuc. MTCH2 and AGO1 showed
robust readthrough activity (Figure 7B). Readthrough efficiency
was determined by comparison to corresponding in-frame con-
trol constructs where UGA stop codon is replaced with Ala-
encoding GCA. Readthrough efficiency for VEGFA, MTCH2,
and AGO1 was calculated to be 11%, 13%, and 24%,
respectively.
DISCUSSION
Organisms have evolved a plethora of mechanisms at multiple
levels to expand their proteomes relative to their surprisingly
limited number of distinct genes. Among the most employed ex-
amples are alternative splicing and alternative polyadenylation at
the posttranscriptional level, alternative initiation at the transla-
tional level, and protein cleavage and modification at the
posttranslational level. There are multiple examples, but little
mechanistic information about proteome expansion by transla-
tional readthrough that can generate proteins with extendedof anti-VEGF-Ax antibody or recombinant human
y as DNA (*p < 0.05, two-way ANOVA).
of bovine ECs in the presence of recombinant His-
red colorimetrically by solid-phase enzyme-linked
min and immunoblotted as shown.
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Figure 7. Genome-wide Analysis to Identify Targets of Translational
Readthrough
(A) Properties of candidate genes selected for experimental validation. Can-
didates were selected using a bioinformatic screening protocol (Figure S6).
(B) Validation of translational readthrough targets. Chimeric plasmids con-
taining about 700 nt of the 30 terminus of human coding sequences (30CDS)
upstream of the interstop codon region (ISR) and in frame with FLuc were
transfected into HEK293 cells. Relative FLuc activities normalized to FLuc
mRNA were determined by qRT-PCR (top). Readthrough efficiency is ex-
pressed as percent of FLuc activity of normal translation controls in which
canonical UGA stop codon is replaced by GCA (bottom). For all graphs, error
bars represent SE; n = 3.
See also Figure S6.C termini and potentially with alternate functions compared to
the shorter, canonical form. Although somemechanistic insights
have been provided by studies of translational readthrough in
RNA viruses, little is known about mechanisms of translational
readthrough in vertebrates and its role in proteome expansion.
Here, we reveal a PTR event in VEGFA transcript that generates
an antiangiogenic isoform, VEGF-Ax. Readthrough events have
been described in vertebrate transcripts, for example, rabbit
b-globin and rat myelin protein zero (Chittum et al., 1998; Yama-
guchi et al., 2012), and a recent ribosome profiling experiment
provided evidence for translational readthrough of 42 mRNAs
in human fibroblasts (Dunn et al., 2013). However, the functional
significance of the readthrough product has not been shown in
any of these cases.
Basal readthrough levels ranging from 0.02% to 1.4% have
been observed in yeast and mammalian cells (Dunn et al.,
2013). In viruses, where multiple readthrough events have
been established, 6% efficiency in murine leukemia virus (MLV)1614 Cell 157, 1605–1618, June 19, 2014 ª2014 Elsevier Inc.and 2%–5% in Sindbis have been reported (Houck-Loomis
et al., 2011; Li and Rice, 1989). In these cases, the nucleotide
sequence downstream of the canonical stop codon serves as
a signal directing readthrough, establishing them as authentic
programmed events unambiguously distinguishable from trans-
lation errors (Firth et al., 2011; Rajon and Masel, 2011). For
example, a 63 nt RNA element downstream of the stop codon
induces translational readthrough in the MLV gag-pol gene
(Houck-Loomis et al., 2011). In our studies, the readthrough effi-
ciency of VEGFA ranges from 7% to 25%. VEGFA mRNA read-
through is programmed by the Ax element, a 63-nt-long RNA
sequence between the two stop codons that can drive read-
through in a heterologous system. We also identify hnRNP A2/
B1 as a trans-factor that binds the A2RE in the Ax element and
positively regulates VEGFA readthrough. This finding is particu-
larly noteworthy in that regulation of translational readthrough by
a trans-factor has not been reported.
Although context-specific regulation of readthrough is sug-
gested by a ribosome profiling study that showed differential
readthrough of nine transcripts in two Drosophila cell types
(Dunn et al., 2013), molecular mechanisms underlying such regu-
lation have not been elucidated in any system. As one possible
mechanism, we speculate that the Ax element, in coordina-
tion with hnRNP A2/B1, interacts directly or indirectly (e.g., by
inducing a pause) with the translating ribosomes and prevents
eukaryotic releasing factor 1 (eRF1) binding to the stop codon.
As a consequence, the UGA stop codon could instead be recog-
nized by a suppressor tRNA or by near-cognate tRNAs resulting
in readthrough. This mechanism is supported by several obser-
vations: (1) protein interactome studies suggest that hnRNP A2/
B1 interacts with several ribosomal proteins, including S7, S19,
S28, L27a, and L39 (Havugimana et al., 2012; Kristensen et al.,
2012); (2) ribosome occupancy is asymmetric at the stop codon,
occupying 6 nt downstream of the stop codon (Ingolia et al.,
2009). The A2RE element starts at the 11th nt following the
stop codon, possibly facilitating an interaction between hnRNP
A2/B1 and a ribosome paused at the stop codon, (3) ami-
noglycosides, which induce readthrough, also bind ribosomes
(Howard et al., 2004; Kondo et al., 2005), and (4) the observed
readthrough of all three stop codons suggests that a single
tRNA species may not be involved. A deep mechanistic under-
standing to the readthrough mechanism might require structural
studies of the relationship of the Ax element and its binding part-
ner with the paused ribosome.
Serine was identified as the amino acid inserted in the place
of the UGA codon during VEGFA mRNA readthrough. Interest-
ingly, the tRNA that inserts selenocysteine (Sec) in place of
UGA codons, namely tRNA[Ser]Sec, specifically recognizes
UGA codons and is initially charged with Ser before it is phos-
phorylated and converted to Sec by Sec synthase (Turanov
et al., 2011). Moreover, Ser-tRNA[Ser]Sec can suppress termina-
tion at a UGA codon in rabbit b-globin mRNA in vitro (Chittum
et al., 1998; Diamond et al., 1981). Thus, Ser-tRNA[Ser]Sec is a
candidate for Ser insertion during VEGFA mRNA readthrough.
Alternatively, a Ser-tRNASer can contribute to readthrough as
a consequence of compromised ribosome fidelity. Although
only Ser was identified in place of the UGA codon of VEGFA
mRNA, other amino acids might be inserted; Trp, Cys, and
Arg are likely candidates, as they have been observed in other
readthrough events involving the UGA stop codon, namely, in
rabbit b-globin (Chittum et al., 1998) and gag-pol MLV (Feng
et al., 1990). However, these and other amino acids likely
constitute a minor fraction, as they were not observed even
after targeted mass spectrometry analysis. The observed read-
through across all stop codon types was unexpected, but
nonsense suppression across all three stop codons has been
reported in mammalian systems (Beier and Grimm, 2001; Hat-
field et al., 1990). Recognition of all three stop codons by
eRF1 is also consistent with our finding of promiscuous read-
through (Kisselev et al., 2003).
Translational readthrough contributes significantly to the pro-
teome expansion in yeast, Drosophila, and human fibroblasts
(Dunn et al., 2013; Jungreis et al., 2011; von der Haar and Tuite,
2007). Using a bioinformatic, genome-wide approach based
on evolutionary conservation of the intrastop codon sequence,
we have identified five additional putative readthrough targets,
none of which have been previously described. Translational
readthrough was experimentally validated in two mRNAs,
AGO1 and MTCH2. MTCH2 induces apoptosis by recruiting
tBID (truncated BH3-interacting domain death agonist) to mito-
chondria (Zaltsman et al., 2010); AGO1 (or EIF2C1) encodes
Argonaute 1, an important participant in the microRNA and
RNAi systems (Kim et al., 2006). Although the other candidates
(NR1D1, TOX1, and ADAMTS4) were inactive in our luciferase-
based readthrough assay in HEK293 cells, they might be
readthrough targets in other conditions or cells. The AGO1 and
MTCH2 30 UTRs do not share sequence similarity with the Ax
element, nor do they possess an A2RE, suggesting that their
readthrough mechanisms are likely to be different from that of
VEGFA mRNA.
The concept of antiangiogenic VEGF-A isoforms was intro-
duced by the report of an alternative splicing event within the
terminal exon of VEGFA to generate VEGFAb mRNA that re-
places CDKPRR at the C terminus with SLTRKD, conferring
antiangiogenic properties in vitro (Bates et al., 2002). Several
laboratories have shown that recombinant or overexpressed
VEGF-Ab inhibits in vivo angiogenesis in murine tumor models,
in mammary tissue of transgenic mice, and during neovascula-
rization in mouse retina, rabbit cornea, and rat mesentery (Ce´be
Suarez et al., 2006, 2008; Cromer et al., 2010; Konopatskaya
et al., 2006; Manetti et al., 2011; Qiu et al., 2008; Rennel
et al., 2008, 2009; Woolard et al., 2004). Lastly, immunological
evidence for robust VEGF-Ab expression has been reported
in multiple cells and tissues (Harper and Bates, 2008).
Despite these promising observations, the in vivo expression
of VEGF-Ab remains controversial, based in part on the obser-
vation that the RT-PCR methods used for detection and quan-
titation are prone to error (Bates et al., 2013; Harris et al., 2012).
Similarly, we were unable to detect VEGFAb mRNA isoforms
in ECs despite robust expression of antiangiogenic activity.
At present, detection by anti-VEGF-Ab antibody is considered
the strongest support for expression of endogenous VEGF-
Ab. However, this evidence is confounded by the presence
of the same SLTRKD hexapeptide at the C termini in both
VEGF-Ax and VEGF-Ab, and anti-VEGF-Ab antibodies raised
against this region do not distinguish between the two isoforms.In contrast, the antibody raised against the first 15 amino acids
of the peptide extension of VEGF-Ax is highly specific for
VEGF-Ax (Figure S2B). New tools and approaches are required
to resolve the relative in vivo expression of the various pro- and
antiangiogenic isoforms. Development of antibodies that recog-
nize VEGF-Ab, but not VEGF-Ax, possibly by targeting the junc-
tion of the sequence encoded by exon 7 and SLTRKD, would
be extremely helpful. Also, RNA sequencing analysis could
not only provide strong support for expression of VEGFAb iso-
forms but also offer insight into the relative amounts of differen-
tially spliced VEGFA and VEGFAb isoforms in a given tissue or
cell type.
VEGF-Ax exhibits potent antiangiogenic activity as evidenced
by inhibition of EC migration, proliferation, and tube formation
in vitro and tumor growth and associated angiogenesis in vivo.
A report of enhanced EC sprouting in aortic rings from mice het-
erozygous for EC-specific VEGFA gene deletion (da Silva et al.,
2010) is consistent with our finding of predominant antiangio-
genic VEGF-Ax in EC-conditioned medium. The discovery of
antiangiogenic VEGF-A isoforms compels a need for cognizance
and caution in applying VEGF-A-targeted therapies for treatment
of VEGF-A-dependent malignancies, as coincident diminution
of VEGF-Ax may exacerbate angiogenesis and tumorigenesis
(Harper and Bates, 2008; Varey et al., 2008). Moreover,
usefulness of VEGF-A as a biomarker might also need to be
reconsidered in the view of potential presence of both pro-
and antiangiogenic isoforms. We speculate that expression
of VEGF-Ax is an innate mechanism that evolved to limit EC
movement and angiogenesis during tissue homeostasis and to
reduce pathological angiogenesis. However, in some conditions
exemplified by colon adenocarcinoma in our study, a loss of
expression of VEGF-Ax might induce angiogenesis and exacer-
bate pathogenesis. Thus, abnormally low levels of VEGF-Ax
in plasma or tissues can serve as a biomarker for prognosis
or effective susceptibility to current anti-VEGF treatment. More-
over, because of its robust antiangiogenic activity, VEGF-Ax
provides a potential therapeutic agent against diseases charac-
terized by excessive angiogenesis.EXPERIMENTAL PROCEDURES
Cell Culture
Bovine aortic ECs were cultured in Dulbecco’s modified Eagle’s medium
(DMEM)/Ham’s F-12 medium containing 5% fetal bovine serum (FBS) and
used in all experiments unless specified otherwise. Human umbilical vein
ECs (HUVECs) were cultured in EC growth medium with SingleQuots supple-
ments (Lonza). HEK293 cells were cultured in DMEM containing 10% FBS.
Cells were maintained at 37C in a humidified atmosphere with 5% CO2.
Luciferase-Based Translational Readthrough Assay
Plasmids containing chimera of FLuc downstream of test sequences
(VEGFA, Myc, TOX, ADAMTS4, AGO1, NR1D1, or MTCH2) were transfected
(500 ng/well) into bovine ECs or HEK293 cells in 24-well plates using Lipofect-
amine 2000. Plasmid expressing Renilla luciferase (RLuc) (50 ng/well) was
cotransfected as efficiency control. After 48 hr, cells were lysed and FLuc
and RLuc activity were measured using Dual-Luciferase Reporter Assay Sys-
tem (Promega) in a Victor3 1420 Multilabel Plate Counter (Perkin-Elmer). The
same constructs were subjected to in vitro coupled transcription-translation
(500 ng/reaction) using TNT T7 coupled rabbit reticulocyte lysates (Promega)
and FLuc activity measured by Luciferase Assay System (Promega).Cell 157, 1605–1618, June 19, 2014 ª2014 Elsevier Inc. 1615
Animal Studies
Nu/Nu athymic nude male mice were inoculated subcutaneously on both
flanks with HCT116 human colon carcinoma cells. Mice were injected subcu-
taneously with His-VEGF-Ax (10 mg/mouse) obtained fromHEK293 cells stably
expressing bovine VEGF-Ax with Ser in place of the canonical stop codon.
HiTrap Heparin HP Columns (GE Healthcare) were used for purification. Con-
trol mice were injected with buffer containing 25 mM Tris and 150 mM NaCl
(pH 8). Injections were given every third day starting from the fourth day after
tumor inoculation. Tumor progression was monitored by caliper determination
of volume [(shortest diameter)2 3 (longest diameter) 3 0.525]. For determina-
tion of tumor angiogenesis, treatment was started on the second day after
tumor inoculation, and blood vessels feeding directly into day 6 tumors
were counted under a dissecting microscope at 12.53 magnification. Images
were captured using PSMT5 operating microscope (World Precision) with 12.5
3 objective lens; every visible vessel touching the circumference of the tumor
nodule was scored as a single vessel by an observer blinded to the treatment.
Animal studies were conducted under the oversight of Animal Research
Committee of the Cleveland Clinic. Animals were housed in the animal
facility of Cleveland Clinic accredited by the Association and Accreditation
of Laboratory Animal Care.
For further detail, please see Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
six figures and can be found with this article online at http://dx.doi.org/10.
1016/j.cell.2014.04.033.
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